You Searched For: [(3S)-1,4-Dioxaspiro[4.5]decan-3-yl]methanol

42,519 results were found

Refine Results Sort by

Sort Results

List View Easy View

Compare(0) Clear

Rate These Search Results

[(3S)-1,4-Dioxaspiro[4.5]decan-3-yl]methanol 95%

Supplier: Apollo Scientific

Description: [(3S)-1,4-Dioxaspiro[4.5]decan-3-yl]methanol 95%

1,4-Dioxaspiro[4.5]decane-8-methanol

Supplier: Apollo Scientific

Description: 1,4-Dioxaspiro[4.5]decane-8-methanol

Nigericin sodium salt ≥98%

Catalog Number: (ENZOBMLCA4210005)

Supplier: ENZO LIFE SCIENCES AG

Description: NALP3 activator

UOM: 1 * 5 mg

New Product Sale

Retrieving Each

Nigericin sodium salt

Supplier: Apollo Scientific

Description: Nigericin sodium salt

Certificates

1-(1,4-Dioxaspiro[4.5]dec-8-yl)-ethanone

Catalog Number: (APOSOR451156-1G)

Supplier: Apollo Scientific

Description: 1-(1,4-Dioxaspiro[4.5]dec-8-yl)-ethanone

UOM: 1 * 1 g

Sale

Retrieving Each

WYE-125132 ≥99% (by HPLC)

Supplier: ENZO LIFE SCIENCES AG

Description: Highly potent, ATP-competitive, and specific mTOR kinase inhibitor. Antiproliferative.

New Product

WYE-125132 ≥98%, crystalline solid

Supplier: Cayman Chemical

Description: WYE-125132 is an ATP-competitive inhibitor of mTOR (IC50 = 0,19 nM) that inhibits signaling through both mTORC1 and mTORC2. It is selective for mTOR over phosphatidylinositol 3-kinase isoforms. WYE-125132 is effective against mTORC1 and mTORC2 in diverse cancer models, both in vitro and in vivo. Oral administration of WYE-125132 alone blocks mTOR signaling and prevents tumor growth in breast, lung, renal, and glioma cancer xenografts in mice, while combination therapy with the VEGF-inhibitor bevacizumab causes complete regression of A498 renal carcinoma tumors. In addition to its applications in cancer, WYE-125132 has been used to delineate novel aspects of mTOR signaling.